In the late 1960s, researchers at the Weizmann Institute of Science, including Professors Michael Sela and Ruth Arnon and Dr.

The analyst firm said the company looked likely to gain final clearance to market its generic version of Teva's multiple sclerosis drug Copaxone (glatiramer) in the near future. Copaxone is a ...